This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other endocrine disorders
  • /
  • Telotristat ethyl: a novel agent for the therapy o...

Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.

Read time: 1 mins
Published:19th Jan 2018
Author: Dillon JS, Chandrasekharan C.
Source: Future Oncology
Availability: Pay for access, or by subscription
Ref.:Future Oncol. 2018.
Carcinoid syndrome (CS), characterized by diarrhea and flushing, is present in 20% of patients with neuroendocrine tumors at diagnosis and becomes more frequent with progression. The diarrhea of CS is caused mainly by tumoral secretion of serotonin. It may not be fully controlled by somatostatin analogs, the currently indicated drugs for symptomatic relief. Telotristat ethyl is a novel inhibitor of tryptophan hydroxylase, the rate-limiting enzyme in serotonin biosynthesis. Administration of the drug decreases diarrhea in patients with CS. Telotristat ethyl was approved in February 2017 (USA) and September 2017 (European Commission) for the treatment of CS diarrhea in adults inadequately controlled by somatostatin analog alone. This drug is expected to greatly improve the health and quality of life of patients with CS diarrhea.

Read abstract on library site

Access full article